anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Callout

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 96,741
Current window 76,651-76,680
Pages 3,225
Rows per page 30
Component: Calloutclear collectionreset all
18 30 60

Component

76,651-76,680 of 96,741

filter-aware
04
The slide presents qualitative evidence from industry representatives to frame AXDX's competitive position as limited by its narrow focus on blood stream infections and reliance on surrogate measurements.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Problem (Identify pain)1 hit
05
The slide uses external citations (FDA approval, peer-reviewed article, ECCMID poster) to build a negative case against the subject technology.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Problem (Identify pain)Loop · Zoom In1 hit
06
The slide uses a Q&A format to highlight technical and operational weaknesses in the AXDX Pheno system.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Problem (Identify pain)Loop · Zoom In1 hit
07
The slide uses a combination of technical critique and competitive intelligence (QuantaMatrix interview) to undermine the value proposition of the Pheno system.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Problem (Identify pain)Loop · Zoom In1 hit
08
The slide presents qualitative evidence from industry interviews and literature to argue against the economic viability of the Pheno system.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Problem (Identify pain)Loop · Zoom In1 hit
09
The slide uses a Q&A format to present anecdotal evidence from industry reps and a physician to challenge the market value of rapid diagnostic systems.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Problem (Identify pain)Loop · Zoom In1 hit
10
The slide uses a rhetorical question to challenge the value proposition of rapid diagnostics in the context of standard sepsis care protocols.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Agitate (Make it worse)1 hit
12
The slide includes an embedded image of a conference presentation slide showing a diagnostic validity funnel.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Agitate (Make it worse)1 hit
13
The slide uses a screenshot of a company presentation to frame a contradiction, then provides a textual rebuttal based on study methodology.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Agitate (Make it worse)1 hit
14
The slide uses a timeline diagram to illustrate the reduction in time-to-result for blood culture testing.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Agitate (Make it worse)1 hit
15
The slide uses a timeline diagram and a comparison table to challenge AXDX's claimed 75% time advantage.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Agitate (Make it worse)1 hit
16
The slide uses quotes from management (Reichling, Mehren) to demonstrate a deterioration in business metrics over time, specifically comparing Q2 2018 and Q2 2019 expectations.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
17
The slide explains the methodology for deriving average instrument revenue percentages from disparate analyst reports.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
18
The table reconstructs cumulative totals based on the provided bar chart data.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
19
The slide explains the logic behind calculating 'functional system-months' based on contract timing and provides a supporting data table.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
20
The slide contains two tables: one showing quarterly data points and another showing column headers for a larger dataset.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
21
The slide uses a data table to expose a discrepancy between management's claims and the analyst's model.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
22
The chart shows a clear downward trend in reagent revenue per system from Q4 2017 to Q2 2019.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
23
Includes a Q&A excerpt from an investor relations call highlighting the lack of binding minimum test requirements.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
24
The slide contains a series of Q&A exchanges followed by a concluding synthesis paragraph.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
25
The slide uses a bearish investment research tone, highlighting risks to the company's business model and clinical validation.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
26
This is a short-seller research note analyzing the timeline of a clinical study and management's subsequent actions.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
27
The slide contrasts optimistic management commentary from 2018 with a more cautious tone in 2019.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
28
The slide uses a quote-based analysis to question the credibility of management's focus on 'time to optimal therapy' over 'mortality and length of stay'.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller 1 hit
30
Includes a direct quote from Lawrence Mehren (CEO) to support the argument.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Solution (Provide relief)1 hit
31
The slide uses a skeptical tone to challenge management's guidance, citing specific quarterly placement figures (133, 75, 55) to highlight a downward trend.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
32
The text highlights a contradiction between management's narrative of 'better pricing' strategy and the observed low compliance in clinical studies.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
33
The slide contrasts positive clinical trial data (PHENOMENON study) with negative market sentiment from a sell-side analyst survey.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
34
The slide presents a bearish thesis on AXDX based on primary research (lab surveys) and reimbursement analysis.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
35
Includes a transcript excerpt from a Q2 2019 earnings call regarding NTAP program applications.Accelerate Diagnostics (AXDX) · White Diamond Research
Research note Short seller Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit